Multimedia

Michael Ganio, PharmD, senior director, pharmacy practice and quality, ASHP, discusses 2020 drug shortage trends, highlights how NDMA exposure can be improved during the manufacturing process, and provides a future prediction on how he sees...

Tom Kraus, vice president of government relations, ASHP, discusses drug pricing trends seen over the past 12 months and highlights what is expected as 2021 approaches.

Anna Legreid Dopp, PharmD, senior director of clinical guidelines and quality improvement, ASHP, provides the need-to-know details of the COVID-19 vaccine, including how the vaccine rollout will impact the everyday work of a pharmacist as...

Victor G Vogel, MD, medical oncologist, Geisinger Health System, discusses a variety of risk reducing strategies for breast cancer, including why some are “overdue,” explains why there is a lack in the uptake of medications among patients...

Anthony Mato, MD, Memorial Sloan Kettering Cancer Center, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with chronic lymphocytic leukemia (CLL) in the clinical practice setting, using the informCLL...

Based on a median follow-up of four years, John Allen, MD, assistant professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine, New York-Presbyterian Hospital, explains how first-line ibrutinib-based...

William G. Wierda, MD, PhD, professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, discusses the results of the Phase II CAPTIVATE study, and highlights how the use of Ibrutinib plus Venetoclax confers high rates of...

Alfred L Garfall, MD, MS, assistant professor of Medicine, Perelman School of Medicine, University of Pennsylvania, discusses his recent study presented at ASH 2020, which examined the use of teclistamab for the treatment of multiple myeloma,...